热门资讯> 正文
ViiV扩大在低收入国家生产仿制药Apretude的许可证
2025-07-14 23:58
- ViiV Healthcare, which is majority owned by GSK (NYSE:GSK), said it will expand a licensing agreement with the Medicines Patent Pool that will allow manufacturers to produce generic Apretude (cabotegravir) for low-income countries as a long-acting HIV treatment.
- Previously, the agreement only allowed for generic cabotegravir production for HIV prevention.
- Existing licensees are Aurobindo, Cipla, and Viatris (NASDAQ:VTRS).
- Generic Apretude should be used in combination with Johnson & Johnson's (JNJ) Edurant (rilpivirine), ViiV stated.
- Pfizer (NYSE:PFE) and Shionogi (OTCPK:SGIOY)(OTCPK:SGIOF) are minority shareholders in ViiV.
More on GSK
- GSK's Specialty Medicines Surge - Still Looks Undervalued In 2025
- 5 Reasons GSK Looks Good
- GSK plc (GSK) Q1 2025 Earnings Conference Call Transcript
- GSK’s RSV vaccine to be reviewed by FDA for expanded use
- Zantac makers handed court win in Delaware
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
